Azurocidin, Human Neutrophil (Cationic protein 37) recombinant protein
Cationic antimicrobial protein CAP37, Heparin-binding protein
|Calculated MW||37 kDa|
|Other Names||Cationic antimicrobial protein CAP37, Heparin-binding protein|
|Source||Human Neutrophil. Prepared from whole blood shown to be non-reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.|
|Application Notes||Use deionized water|
|Storage||-20°C; Salt-free lyophilized solid.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The gene for azurocidin is located on the short arm of chromosome 19 and is in a cluster with the genes for proteinase 3 and elastase. All three proteins are serine protease homologues; azurocidin, however, lacks enzymatic activity. It is an antibiotic protein, with monocyte chemotactic and antibacterial activity. The Azurophil granules, specialized lysosomes of the neutrophil, contain at least 10 proteins implicated in the killing of microorganisms. Azurocidin is a member of the serine protease family that includes Cathepsin G, Neutrophil Elastase (NE), and Proteinase 3 (PR3), however, Azurocidin is not a serine proteinase since the active site serine and histidine residues are replaced. Azurocidin has been identified as a modulator of endothelial permeability and an important multifunctional inflammatory mediator. Neutrophils arriving first at sites of inflammation release Azurocidin which acts in a paracrine fashion on endothelial cells causing the development of intercellular gaps and allowing leukocyte extravasation. Azurocidin thus be regarded as a reasonable therapeutic target for a variety of inflammatory disease conditions.
Morgan J.G.,et al.J. Immunol. 147:3210-3214(1991).
Zimmer M.,et al.Proc. Natl. Acad. Sci. U.S.A. 89:8215-8219(1992).
Grimwood J.,et al.Nature 428:529-535(2004).
Almeida R.P.,et al.Biochem. Biophys. Res. Commun. 177:688-695(1991).
Pohl J.,et al.FEBS Lett. 272:200-204(1990).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.